CAS 72496-41-4
:Pirarubicina
Descripción:
Pirarubicina, con el número CAS 72496-41-4, es un antibiótico antraciclínico que se utiliza principalmente como agente antineoplásico en la terapia del cáncer. Está estructuralmente relacionado con la doxorubicina y exhibe mecanismos de acción similares, principalmente intercalándose en el ADN, inhibiendo así la síntesis de ADN y ARN, lo que lleva a la muerte celular. Pirarubicina es particularmente efectivo contra varios tipos de cáncer, incluyendo el cáncer de mama y la leucemia. Su perfil farmacológico incluye un nivel de citotoxicidad moderado a alto, y a menudo se administra por vía intravenosa. El fármaco es conocido por sus posibles efectos secundarios, que pueden incluir cardiotoxicidad, mielosupresión y trastornos gastrointestinales. Debido a su estructura química, Pirarubicina también puede generar especies reactivas de oxígeno, contribuyendo a sus efectos anticancerígenos. El compuesto se utiliza típicamente en combinación con otros agentes quimioterapéuticos para mejorar la eficacia terapéutica mientras se maneja la resistencia. Al igual que con todos los agentes quimioterapéuticos, el monitoreo cuidadoso de los pacientes es esencial para mitigar los efectos adversos y optimizar los resultados del tratamiento.
Fórmula:C32H37NO12
InChI:InChI=1/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19?,21+,22-,31+,32-/m0/s1
Clave InChI:InChIKey=KMSKQZKKOZQFFG-YXRRJAAWSA-N
SMILES:O([C@@H]1C2=C(C(O)=C3C(=C2O)C(=O)C=4C(C3=O)=CC=CC4OC)C[C@](C(CO)=O)(O)C1)[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5
Sinónimos:- (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-4-O-[(2S)-tetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranoside
- (2''R)-4'-O-Tetrahydropyranyladriamycin
- (2′′R)-4′-O-Tetrahydropyranyladriamycin
- (2′′R)-4′-O-Tetrahydropyranyldoxorubicin
- (3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranoside
- (8S,10S)-10-((3-Amino-2,3,6-trideoxy-4-O-(2R-tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
- (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
- 1609Rb
- 4'-O-Tetrahydropyranyladriamycin
- 4'-O-Tetrahydropyranyldoxorubicin
- 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
- 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8α,10α(S*)]]-
- 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
- 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
- Pinorubicin
- Pirarubicin Hydrochloride
- Pirarubicin [INN:JAN]
- Pirarubicina
- Pirarubicina [Spanish]
- Pirarubicine
- Pirarubicine [French]
- Pirarubicinum
- Pirarubicinum [Latin]
- THP-adriamycin
- Therarubicin
- (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
- 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
- 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
- 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8α,10α(S*)]]-
- (8S)-10α-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
- l)-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hy
- (7S,9S)-7-((2R,4S,5S,6S)-4-amino-6-methyl-5-((R)-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
- 5,12-naphthacenedione,10-((3-amino-2,3,6-trideoxy-4-o-(tetrahydro-2h-pyran-2-y
- (8s-cis)-droxyacetyl)-1-methoxy
- (8S)-10-[(2S,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
- 5,12-Naphthacenedione, 10-3-amino-2,3,6-trideoxy-4-O-(2R)-tetrahydro-2H-pyran-2-yl-.alpha.-L-lyxo-hexopyranosyloxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
- THP-ADM
- Pirarubicin(THP-AdriaMycin)
- THEPRUBICIN
- Therarubiein
- Pirarubicin(BICINS)
- Pirabucin
- PIRARUBICIN
- (8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
- (8S,10S)-10α-[[3-Amino-4-O-(tetrahydro-2H-pyran-2-yl)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-hydroxyacetyl-1-methoxy-5,12-naphthacenedione
- Ver más sinónimos
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
Se han encontrado 9 productos.
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
CAS:Fórmula:C32H37NO12Pureza:98%Forma y color:SolidPeso molecular:627.6357Pirarubicin
CAS:Pirarubicin (Theprubicin), an anthracycline antibiotic, inhibits DNA/RNA synthesis and is used as an antineoplastic.Fórmula:C32H37NO12Pureza:97.80% - 99.15%Forma y color:SolidPeso molecular:627.6357Pirarubicin
CAS:Fórmula:C32H37NO12Pureza:≥ 95%Forma y color:Red to orange powderPeso molecular:627.64Pirarubicin
CAS:Antibiotic of anthracycline class; DNA synthesis inhibitorFórmula:C32H37NO12Pureza:Min. 95%Forma y color:PowderPeso molecular:627.64 g/molPirarubicin
CAS:(8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-6-methyl-5-(((R)-tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dioneFórmula:C32H37NO12Pureza:98%Peso molecular:627.64Pirarubicin
CAS:Producto controladoApplications Structural analog of Doxorubicin. Antineoplastic.
References Umezawa, H., et al.: J. Antibiot., 32, 1082 (1979), Majima, H., et al.: Biomed. Pharmacother., 41, 237 (1987), Miller, A.A., et al.: Cancer Res., 47, 1461 (1987), Fallik, D., et al.: Ann. Ocol., 14, 856 (2003),Fórmula:C32H37NO12Forma y color:NeatPeso molecular:627.64







